"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial looking at enzastaurin and temozolomide for gliomas (EORTC 26054)
This trial looked at different doses of enzastaurin and temozolomide for glioma brain tumours.
In this trial, the researchers wanted to learn more about having enzastaurin at the same time as temozolomide. They hoped that enzastaurin (LY317615) may be able to stop the cancer developing its own blood supply. This is called anti angiogenesis. Other trials had shown that enzastaurin may help people with gliomas, but doctors wanted to find out if it is safe to have this drug at the same time as temozolomide.
The aims of this trial were to find out
- The best doses of enzastaurin and temozolomide when you have both drugs at the same time
- What the side effects are
- If having temozolomide and enzastaurin together helps people with a glioma
Summary of results
The research team found that the combination of enzastaurin and temozolomide was safe, and they recommended a dose to use for future trials.
This phase 1 trial recruited 28 people with glioma that was either newly diagnosed or had come back after treatment. The research team were able to analyse the results of 26 of them.
The people taking part had 1 of 3 doses of enzastaurin
- A lower dose, once a day
- A lower dose, twice a day
- A higher dose, once a day
The research team found that the people who had the lower dose twice a day had the most side effects. They concluded that the best dose to use was the higher dose, once a day.
It is difficult to draw firm conclusions about how well treatment works in a trial this small, but they found that during the trial
- 3 people’s cancer stopped growing
- 15 people’s cancer stayed the same size
- 8 people’s cancer continued to grow
The trial team concluded that enzastaurin and temozolomide could be a useful combination for people with glioma. They also recommended a dose of enzastaurin to be used in future trials.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Roy Rampling
Eli Lilly and Company Limited
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)